In the phase 3 Impower110 trial [32], atezolizumab showed a significant and clinically meaningful survival benefit over chemotherapy in previously untreated patients with advanced NSCLC with high PD-L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.